George Zachary

George Zachary established CRV’s Bioengineering practice in August of 2016. In addition to investing in Glympse, he has led the firm’s investments in PillPack, a full-service, technology-based pharmacy that was acquired by Amazon in 2018; Wild Type, a company who creates clean and sustainable fish and meat through cellular agriculture technologies; System1 Biosciences, a neurotherapeutics company that employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases; Freenome, a company applying deep learning to cell-free DNA for early cancer detection; HealthIQ, a technology-based insurance company that uses artificial intelligence to provide the best rates for health-conscious individuals; Color Genomics; and Recursion Pharma. He was also the first and lead institutional investor in a number of the world’s most iconic companies including Twitter (TWTR), Yammer ($1B acquisition by MSFT), Shutterfly (SFLY), and Udacity.

George has over 20 years of computing and consumer technology experience to his role as an investor, having previously been a general partner at Mohr Davidow Ventures (MDV), and leading the Nintendo 64 development business at Silicon Graphics. He earned a joint B.S. in Computer Science and Management Science from MIT and MIT